Manager TitleAgeSince
Chief Executive Officer 43 01/01/2016
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 10/03/2022
Director TitleAgeSince
Director/Board Member 71 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
01/12/22 Issuer sale

Director

16,000 0.0433%
01/12/22 Issuer sale

Director

55,030 0.1489%
01/12/22 Issuer sale

Chief Financial Officer

150,000 0.4060%
Change 5-day change 1-year change 3-year change Capi.($)
+1.06%+0.91% - - 491M
-0.81%-0.33%+27.15%+81.12% 55.23B
+0.67%-6.81%+26.11%+64.03% 53.75B
-0.44%+4.15%-13.45%-14.54% 23.48B
-0.77%-4.91%-5.23%+360.25% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
+0.09%-1.65%+28.52%-33.71% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
-2.10%+1.08%+54.53%+183.97% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average -0.52%-1.55%+34.15%+160.17% 25.94B
Weighted average by Cap. -0.42%-0.44%+27.29%+123.08%
Logo AKOUOS
Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
Employees
103
  1. Stock Market
  2. Stocks
  3. AKUS Stock